Epigenomics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 1/6
Epigenomics has a total shareholder equity of €-8.3M and total debt of €11.4M, which brings its debt-to-equity ratio to -136.9%. Its total assets and total liabilities are €12.0M and €20.4M respectively. Epigenomics's EBIT is €4.2M making its interest coverage ratio 134.3. It has cash and short-term investments of €1.2M.
Anahtar bilgiler
-136.9%
Borç/özkaynak oranı
€11.42m
Borç
| Faiz karşılama oranı | 134.3x |
| Nakit | €1.21m |
| Eşitlik | -€8.34m |
| Toplam yükümlülükler | €20.38m |
| Toplam varlıklar | €12.04m |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: ECX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Uzun Vadeli Yükümlülükler: ECX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: ECX has negative shareholder equity, which is a more serious situation than a high debt level.
Borcun Azaltılması: ECX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Borç Kapsamı: ECX's operating cash flow is negative, therefore debt is not well covered.
Faiz Kapsamı: ECX's interest payments on its debt are well covered by EBIT (134.3x coverage).